Adial Pharmaceuticals, Inc. (ADIL) Insider Trading Activity

NASDAQ$5.89-0.76 (-11.43%)
Market Cap
$6.38M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
297 of 853
Rank in Industry
169 of 492

ADIL Insider Trading Activity

ADIL Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$106,329
5
100
Sells
$0
0
0

Related Transactions

Coastlands Capital LP10 percent owner
5
$106,329
0
$0
$106,329

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.

Insider Activity of Adial Pharmaceuticals, Inc.

Over the last 12 months, insiders at Adial Pharmaceuticals, Inc. have bought $106,329 and sold $0 worth of Adial Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Adial Pharmaceuticals, Inc. have bought $86,372 and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Coastlands Capital LP (10 percent owner) — $106,329.

The last purchase of 1,233 shares for transaction amount of $3,391 was made by Coastlands Capital LP (10 percent owner) on 2026‑07‑16.

List of Insider Buy and Sell Transactions, Adial Pharmaceuticals, Inc.

2026-07-16PurchaseCoastlands Capital LP10 percent owner
1,233
0.1299%
$2.75
$3,391
+54.48%
2026-07-14PurchaseCoastlands Capital LP10 percent owner
2,000
0.2084%
$2.65
$5,300
+62.64%
2026-07-10PurchaseCoastlands Capital LP10 percent owner
1,700
0.1721%
$2.70
$4,590
+51.44%
2026-07-09PurchaseCoastlands Capital LP10 percent owner
10,053
1.0438%
$2.79
$28,048
+47.50%
2026-06-29PurchaseCoastlands Capital LP10 percent owner
25,000
2.6152%
$2.60
$65,000
+46.72%
2023-09-29PurchaseSchuyler Kevindirector
700
0.0566%
$2.74
$1,918
-50.18%
2021-12-30PurchaseNewman James W. Jr.director
25,000
0.1356%
$2.69
$67,300
-53.00%
2021-11-30PurchaseStilley William B. IIIChief Executive Officer
10,600
0.0565%
$2.75
$29,179
-51.80%
2021-11-29PurchaseStilley William B. IIIChief Executive Officer
10,000
0.0544%
$2.59
$25,892
-47.27%
2021-11-26PurchaseNewman James W. Jr.director
10,000
0.0538%
$2.85
$28,500
-52.28%
2021-04-06SaleJohnson Bankole A.Chief Medical Officer
150,000
0.8494%
$2.50
$375,000
+4.38%
2020-08-20SaleJohnson Bankole A.Chief Medical Officer
350,000
2.0553%
$1.21
$423,500
+47.02%
2020-03-27PurchaseNewman James W. Jr.director
19,644
0.1848%
$1.36
$26,769
+23.91%
2020-03-26PurchaseStilley William B. IIIChief Executive Officer
12,652
0.1363%
$1.47
$18,598
+31.54%
2020-03-25PurchaseStilley William B. IIIChief Executive Officer
12,348
0.1072%
$1.13
$13,953
+37.90%
2019-12-12SaleJohnson Bankole A.Chief Medical Officer
150,000
0.8506%
$1.00
$150,000
-7.44%
2019-03-29PurchaseJohnson Bankole A.Chief Medical Officer
33,100
0.4057%
$3.47
$114,801
-50.44%
2019-03-28PurchaseJohnson Bankole A.Chief Medical Officer
40,000
0.4706%
$3.15
$125,808
-47.53%
2018-07-31PurchaseStilley William B. IIIChief Executive Officer
80,000
1.8029%
$5.00
$400,000
-28.75%
2018-07-31PurchaseSchuyler Kevindirector
180,000
2.0282%
$2.50
$450,000
-28.75%
Total: 24
*Gray background shows transactions not older than one year

ADIL Institutional Investors: Active Positions

Increased Positions11+68.75%118,302+486.36%
Decreased Positions5-31.25%1,177-4.84%
New Positions7New110,719New
Sold Out Positions<1Sold Out448Sold Out
Total Postitions22+37.5%141,449+481.52%

ADIL Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Geode Capital Management, Llc$39.000.61%164,127+95,277+138.38%2025-09-30
Vanguard Group Inc$37.000.58%156,024+142,865+1,085.68%2025-09-30
Citadel Advisors Llc$34.000.53%143,791+143,791New2025-09-30
Manchester Capital Management Llc$11.000.18%48,09700%2025-09-30
Blackrock, Inc.$7.000.1%27,77000%2025-09-30
Ubs Group Ag$4.000.07%18,758+6,363+51.34%2025-09-30
Two Sigma Securities, Llc$3.000.05%12,841+12,841New2025-09-30
Jane Street Group, Llc$3.000.05%12,341-12,521-50.36%2025-09-30
Hrt Financial Lp$3.000.04%11,191-7,899-41.38%2025-09-30
Private Management Group Inc$2.000.04%10,000+10,000New2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.